BR112014012414A2 - processo para a preparação de 5-flúor-1h-pirazolopiridinas substituídas - Google Patents

processo para a preparação de 5-flúor-1h-pirazolopiridinas substituídas

Info

Publication number
BR112014012414A2
BR112014012414A2 BR112014012414A BR112014012414A BR112014012414A2 BR 112014012414 A2 BR112014012414 A2 BR 112014012414A2 BR 112014012414 A BR112014012414 A BR 112014012414A BR 112014012414 A BR112014012414 A BR 112014012414A BR 112014012414 A2 BR112014012414 A2 BR 112014012414A2
Authority
BR
Brazil
Prior art keywords
pyrazolopyridines
fluoro
substituted
preparation
Prior art date
Application number
BR112014012414A
Other languages
English (en)
Other versions
BR112014012414B1 (pt
BR112014012414A8 (pt
Inventor
Fey Peter
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Priority to BR122020001312-5A priority Critical patent/BR122020001312B1/pt
Publication of BR112014012414A2 publication Critical patent/BR112014012414A2/pt
Publication of BR112014012414A8 publication Critical patent/BR112014012414A8/pt
Publication of BR112014012414B1 publication Critical patent/BR112014012414B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
BR112014012414-0A 2011-11-25 2012-11-21 Processos para preparar 5-flúor-1h-pirazolopiridinas substituídas BR112014012414B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020001312-5A BR122020001312B1 (pt) 2011-11-25 2012-11-21 Processo para preparação de 5-flúor-1h-pirazolopiridinas substituídas, e compostos intermediários

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11190789.5 2011-11-25
EP11190789 2011-11-25
EP11192301.7 2011-12-07
EP11192301 2011-12-07
PCT/EP2012/073276 WO2013076168A1 (de) 2011-11-25 2012-11-21 Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Publications (3)

Publication Number Publication Date
BR112014012414A2 true BR112014012414A2 (pt) 2017-06-06
BR112014012414A8 BR112014012414A8 (pt) 2018-01-23
BR112014012414B1 BR112014012414B1 (pt) 2022-01-11

Family

ID=47222101

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020001312-5A BR122020001312B1 (pt) 2011-11-25 2012-11-21 Processo para preparação de 5-flúor-1h-pirazolopiridinas substituídas, e compostos intermediários
BR112014012414-0A BR112014012414B1 (pt) 2011-11-25 2012-11-21 Processos para preparar 5-flúor-1h-pirazolopiridinas substituídas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020001312-5A BR122020001312B1 (pt) 2011-11-25 2012-11-21 Processo para preparação de 5-flúor-1h-pirazolopiridinas substituídas, e compostos intermediários

Country Status (42)

Country Link
US (7) US8802847B2 (pt)
EP (3) EP2896617B1 (pt)
JP (4) JP6189315B2 (pt)
KR (3) KR102026059B1 (pt)
CN (3) CN106905314A (pt)
AP (2) AP2014007705A0 (pt)
AR (1) AR088983A1 (pt)
AU (3) AU2012342547C1 (pt)
BR (2) BR122020001312B1 (pt)
CA (2) CA3040720C (pt)
CL (2) CL2014001339A1 (pt)
CO (1) CO6960555A2 (pt)
CR (3) CR20190057A (pt)
CU (3) CU24354B1 (pt)
CY (1) CY1124000T1 (pt)
DK (3) DK2782914T3 (pt)
DO (3) DOP2014000112A (pt)
EA (4) EA033455B1 (pt)
EC (1) ECSP14001627A (pt)
ES (3) ES2603028T3 (pt)
GT (1) GT201400101A (pt)
HK (2) HK1203951A1 (pt)
HR (3) HRP20161501T1 (pt)
HU (3) HUE031029T2 (pt)
IL (3) IL232585A0 (pt)
JO (3) JOP20120351B1 (pt)
LT (3) LT2782914T (pt)
MX (1) MX357481B (pt)
MY (3) MY198086A (pt)
PE (3) PE20142359A1 (pt)
PH (2) PH12014501160A1 (pt)
PL (3) PL3421470T3 (pt)
PT (3) PT2782914T (pt)
RS (3) RS61609B1 (pt)
SG (3) SG10201604192XA (pt)
SI (3) SI3421470T1 (pt)
TR (1) TR201816203T4 (pt)
TW (5) TWI597280B (pt)
UA (3) UA120278C2 (pt)
UY (2) UY34467A (pt)
WO (1) WO2013076168A1 (pt)
ZA (2) ZA201403613B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
UA120278C2 (uk) 2011-11-25 2019-11-11 Адверіо Фарма Гмбх Заміщені 5-фтор-1н-піразолопіридини в кристалічній формі
BR112015019571A2 (pt) 2013-02-21 2017-07-18 Adverio Pharma Gmbh formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
MX2018007152A (es) 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3609883B1 (en) 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
EP3820476A1 (en) 2018-07-11 2021-05-19 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
AU2019409269A1 (en) 2018-12-17 2021-06-03 Adverio Pharma Gmbh Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof
CN113272286B (zh) * 2019-01-22 2024-04-16 阿德弗里奥药品有限责任公司 制备4-(2,2,3,3-四氟丙基)吗啉的方法
WO2021156223A1 (en) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2023034364A1 (en) 2021-08-31 2023-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of vericiguat and process for preparation thereof
ES2956054A1 (es) * 2022-05-03 2023-12-12 Moehs Iberica Sl 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
CN115043835B (zh) * 2022-06-17 2023-05-09 常州制药厂有限公司 一种维立西呱的精制纯化方法
WO2024038398A1 (en) * 2022-08-18 2024-02-22 Torrent Pharmaceuticals Limited Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8606936D0 (en) * 1986-03-20 1986-04-23 Ici Plc Organic compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
SK6722001A3 (en) * 1998-11-16 2001-12-03 Basf Ag Herbicidal 3-[benzo(ox/thi)azol-7-yl]-1h-pyrimidine-2,4-diones
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10131987A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Pyridin-substituierte Pyrazolopyridinderivate
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2429308C (en) 2000-11-22 2010-09-21 Bayer Aktiengesellschaft Novel lactam-substituted pyrazolopyridine derivatives
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DK1401445T3 (da) 2001-06-22 2006-11-27 Boehringer Ingelheim Pharma Krystallinsk anticholinergikum, fremgangsmåde til fremstilling af dette og anvendelse af dette til fremstilling af et lægemiddel
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006031175A1 (de) 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
CA2691888A1 (en) 2007-06-25 2008-12-31 Boehringer Ingelheim International Gmbh New chemical compounds
ES2400104T3 (es) 2007-07-31 2013-04-05 Vertex Pharmaceuticals Incorporated Proceso para preparación de 5-fluoro-1H-pirazolo[3,4-b]piridin-3-amina y derivados de la misma
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
KR100979460B1 (ko) * 2008-05-13 2010-09-02 한국과학기술연구원 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
RS57790B1 (sr) 2009-11-27 2018-12-31 Adverio Pharma Gmbh Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata za njegovu upotrebu kao farmaceutskog aktivnog agensa
UY33040A (es) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX2013000198A (es) 2010-07-09 2013-01-28 Bayer Ip Gmbh Pirimidinadas y triazinas condensadas y su uso.
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
KR20140068112A (ko) 2011-09-02 2014-06-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 융합 피리미딘 및 그의 용도
UA120278C2 (uk) * 2011-11-25 2019-11-11 Адверіо Фарма Гмбх Заміщені 5-фтор-1н-піразолопіридини в кристалічній формі

Also Published As

Publication number Publication date
TW201932465A (zh) 2019-08-16
CL2014001339A1 (es) 2014-10-17
CN104159898A (zh) 2014-11-19
JP2018199698A (ja) 2018-12-20
AP3898A (en) 2016-11-16
AU2019202123A1 (en) 2019-04-18
RS61609B1 (sr) 2021-04-29
EA030018B1 (ru) 2018-06-29
HUE053745T2 (hu) 2021-07-28
EP2896617B1 (de) 2016-10-05
ZA201403613B (en) 2016-02-24
EA201690521A1 (ru) 2016-06-30
AP2015008243A0 (en) 2015-01-31
CA3040720C (en) 2021-06-15
PL2782914T3 (pl) 2019-01-31
MY168412A (en) 2018-11-09
PH12015501494B1 (en) 2015-09-07
DOP2021000179A (es) 2021-09-30
ZA201505970B (en) 2017-08-30
PE20190181A1 (es) 2019-02-01
EP2896617A1 (de) 2015-07-22
NZ721592A (en) 2018-02-23
PT2782914T (pt) 2018-11-16
US20130143900A1 (en) 2013-06-06
JOP20210065A1 (ar) 2023-01-30
US20160009671A1 (en) 2016-01-14
EP2782914A1 (de) 2014-10-01
DOP2014000112A (es) 2014-07-15
IL263389B (en) 2022-03-01
CN105503867B (zh) 2019-01-11
CA2856706C (en) 2020-06-16
PE20142359A1 (es) 2015-01-09
EA201491028A8 (ru) 2016-01-29
TW201838993A (zh) 2018-11-01
TW201329076A (zh) 2013-07-16
EA201491028A1 (ru) 2014-12-30
ES2603028T3 (es) 2017-02-23
EA033455B1 (ru) 2019-10-31
AU2017254916A1 (en) 2017-11-23
CU20140055A7 (es) 2014-10-02
US10633357B2 (en) 2020-04-28
PE20190180A1 (es) 2019-02-01
BR112014012414B1 (pt) 2022-01-11
AP2014007705A0 (en) 2014-06-30
AU2012342547A1 (en) 2014-06-05
LT3421470T (lt) 2021-04-26
LT2782914T (lt) 2018-10-10
HRP20161501T1 (hr) 2016-12-16
CU24354B1 (es) 2018-08-06
UY34467A (es) 2013-06-28
LT2896617T (lt) 2016-12-12
EA031602B1 (ru) 2019-01-31
CR20190057A (es) 2019-04-23
CN104159898B (zh) 2017-01-18
EP3421470B1 (de) 2021-01-20
TW201831447A (zh) 2018-09-01
MX2014006018A (es) 2014-06-04
KR101993022B1 (ko) 2019-06-25
PT2896617T (pt) 2016-11-18
IL246265B (en) 2018-12-31
PH12014501160B1 (en) 2014-10-20
PT3421470T (pt) 2021-03-31
CN106905314A (zh) 2017-06-30
CR20140237A (es) 2014-06-19
IL246265A0 (en) 2016-07-31
UA120278C2 (uk) 2019-11-11
TWI665198B (zh) 2019-07-11
AU2012342547C1 (en) 2019-02-21
US20190177287A1 (en) 2019-06-13
IL263389A (en) 2018-12-31
AU2017254916B2 (en) 2019-02-28
CR20210072A (es) 2021-03-22
US20190177288A1 (en) 2019-06-13
TR201816203T4 (tr) 2018-11-21
NZ724215A (en) 2018-03-23
CN105503867A (zh) 2016-04-20
ECSP14001627A (es) 2015-11-30
JOP20210064A1 (ar) 2023-01-30
US9604948B2 (en) 2017-03-28
JP6189315B2 (ja) 2017-08-30
MX357481B (es) 2018-07-11
BR112014012414A8 (pt) 2018-01-23
CU24257B1 (es) 2017-05-10
PL3421470T3 (pl) 2021-08-02
CU20150123A7 (es) 2016-03-31
AR088983A1 (es) 2014-07-23
KR20140105483A (ko) 2014-09-01
CO6960555A2 (es) 2014-05-30
RS57945B1 (sr) 2019-01-31
CL2016000344A1 (es) 2017-02-10
HRP20181818T1 (hr) 2019-01-11
CY1124000T1 (el) 2022-05-27
UA116623C2 (uk) 2018-04-25
SI2782914T1 (sl) 2018-12-31
MY197904A (en) 2023-07-24
MY198086A (en) 2023-07-31
ES2864009T3 (es) 2021-10-13
SG10201604192XA (en) 2016-07-28
US20140315926A1 (en) 2014-10-23
TWI631123B (zh) 2018-08-01
US20180065942A1 (en) 2018-03-08
KR101943788B1 (ko) 2019-01-29
CA2856706A1 (en) 2013-05-30
PL2896617T3 (pl) 2017-07-31
KR20170130612A (ko) 2017-11-28
AU2019202123B2 (en) 2020-09-24
EP2782914B1 (de) 2018-08-01
TWI659016B (zh) 2019-05-11
NZ624593A (en) 2016-10-28
EP3421470B8 (de) 2021-08-11
TW201708219A (zh) 2017-03-01
US9845300B2 (en) 2017-12-19
EP3421470A1 (de) 2019-01-02
HK1203951A1 (en) 2015-11-06
UY39646A (es) 2022-04-29
CU20150124A7 (es) 2016-03-31
ES2603028T8 (es) 2021-12-29
US10633356B2 (en) 2020-04-28
IL232585A0 (en) 2014-06-30
DK2896617T3 (en) 2016-12-12
AU2012342547B2 (en) 2017-08-17
JP6340391B2 (ja) 2018-06-06
JOP20120351B1 (ar) 2021-08-17
SG11201402111QA (en) 2014-08-28
US10364229B2 (en) 2019-07-30
TWI597280B (zh) 2017-09-01
EA201690520A1 (ru) 2016-07-29
DK2782914T3 (en) 2018-11-26
JP2018058860A (ja) 2018-04-12
EA201892050A1 (ru) 2019-02-28
GT201400101A (es) 2014-11-13
RS55387B1 (sr) 2017-03-31
HUE031029T2 (en) 2017-06-28
ES2694158T3 (es) 2018-12-18
KR20190018021A (ko) 2019-02-20
PH12014501160A1 (en) 2014-10-20
DOP2017000013A (es) 2017-02-15
CA3040720A1 (en) 2013-05-30
HUE041592T2 (hu) 2019-05-28
SG10201604196VA (en) 2016-07-28
JP2015502932A (ja) 2015-01-29
WO2013076168A1 (de) 2013-05-30
SI2896617T1 (sl) 2016-12-30
HRP20210507T1 (hr) 2021-05-28
JP2017031180A (ja) 2017-02-09
HK1223613A1 (zh) 2017-08-04
SI3421470T1 (sl) 2021-07-30
UA119269C2 (uk) 2019-05-27
KR102026059B1 (ko) 2019-09-26
US8802847B2 (en) 2014-08-12
US9150573B2 (en) 2015-10-06
DK3421470T3 (da) 2021-04-06
PH12015501494A1 (en) 2015-09-07
BR122020001312B1 (pt) 2022-02-15
US20170158652A1 (en) 2017-06-08
JP6392436B2 (ja) 2018-09-19

Similar Documents

Publication Publication Date Title
BR112014012414A8 (pt) processo para a preparação de 5-flúor-1h-pirazolopiridinas substituídas
BR112014008196A2 (pt) processo para a preparação de um composto
BR112014005322A2 (pt) processo
BR112014004622A2 (pt) processo para a preparação de isocianatos
BR112014016000A2 (pt) processo
BR112014008911A2 (pt) processo para a produção de 5-hidroximetilfurfural
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BR112014012243A2 (pt) processo de preparação de compostos
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
BR112013008883A2 (pt) processo para a fabricação de di-hidropteridinonas
BR112013031120A2 (pt) processo para a preparação de ácido fórmico
BR112015003101A2 (pt) processo para a preparação de um composto.
BR112014016001A2 (pt) processo
BR112013030423A2 (pt) método para produção de biocoque
BR112014010997A2 (pt) processo para o preparo de ß-glicosídeos de c-arila
BR112014015988A2 (pt) processo
BR112013033184A2 (pt) processo
BR112014001769A2 (pt) processo para a preparação de 1,4-ciclo-hexanodimetanol
BR112014028589A2 (pt) processo para fabricação de compostos de ciclopentilpirimidina hidroxilada
BR112014015999A2 (pt) processo
BR112013022548A2 (pt) processo para a preparação de aminas primárias
BR112014003336A2 (pt) processo para a preparação de complexos de 68ga
BR112015000987A2 (pt) processo para a preparação de 5-fluoro-1h-pirazóis
BR112014014052A2 (pt) processo para a preparação de 5-hidroximetilfurfural
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: ADVERIO PHARMA GMBH (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: ADVERIO PHARMA GMBH (DE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS.